$8m is now my baseline for FY20 (assuming 30% tax rate and no tax asset inclusion), and that's a low baseline given production increases and progress of Alusion sales.
I noticed management were careful when talking about the 2200T capacity. They didn't say it's in excess of current demand - rather, they said it's in excess of "current order intake". Very big difference.
Given how conservative this bunch are, $12m NPAT for FY20 is not unreasonable in the least (again, assumes a full 30% tax and no tax asset realisation, nor R&D benefits). It also doesn't include any benefits from the reduction in 24/7 shift work and the spike in wages as a result.
And correct me if I'm wrong, but Merck might be paying a decent sum of money in FY22 if they want to continue with Alusion exclusivity...
As for the remaining IP - if even 1 in that list works, it's just icing on the cake.
$8m is now my baseline for FY20 (assuming 30% tax rate and no...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
78.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.86M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1922 | 78.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 79.0¢ | 6999 | 1 |
View Market Depth
| Last trade - 16.21pm 04/07/2025 (20 minute delay) ? |
| ANO (ASX) Chart |
Day chart unavailable